To potentiate the expected toxicity profile of single-agent CTLA-4 inhibitors, especially at higher doses as seen in this study and adjuvant trials in cutaneous melanoma [28], future avenues of research are expected to focus on the role of combined checkpoint inhibition with both PD-1 inhibitors and CTLA-4 inhibitors. The gene discussed is CTLA4; the disease is cutaneous melanoma.